B
BAKX Therapeutics
We create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and…
About BAKX Therapeutics
BAKX Therapeutics is a cutting-edge biotechnology startup focused on developing advanced cancer treatments. The company leverages the apoptosis pathway, a natural process of programmed cell death, to create more effective and precise therapeutics. Apoptosis is crucial because it helps eliminate damaged or unnecessary cells, and manipulating this pathway can be a powerful strategy in cancer treatment.
Read full description
BAKX Therapeutics primarily serves the healthcare sector, targeting oncologists, medical researchers, and pharmaceutical companies. The company operates in the highly specialized and competitive oncology market, where there is a constant demand for innovative cancer therapies.
The business model of BAKX Therapeutics revolves around drug discovery and development. The company uses its proprietary integrated drug discovery platform to identify and develop small molecule drugs that target conformationally dynamic proteins (CDPs). CDPs are proteins that change shape and are involved in disease processes, making them attractive targets for new drugs. Historically, CDPs have been challenging to target, but BAKX's advanced computational simulations and deep understanding of disease pathways enable them to overcome these challenges.
BAKX Therapeutics generates revenue through partnerships with larger pharmaceutical companies, licensing its drug candidates, and potentially through the sale of its developed therapeutics once they receive regulatory approval. By focusing on well-validated pathways like the BCL-2 pathway, the company aims to bring transformative cancer therapies to market, addressing unmet medical needs and improving patient outcomes.
At a glance
- Status
- Closed
- Founded
- 2020
- Headquarters
- Kingston, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Cancer Care Companion, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Nov 2021 | $25M | $100M | Ipsen · AB Magnitude Ventures · Sherpa Venture Partners | ↗ |
Growth signals
Latest recorded traffic for BAKX Therapeutics is 550 monthly website visits, down 90.7% over the last three months. BAKX Therapeutics's team declined 42.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Sherpa Venture Partners
Ipsen
AB Magnitude Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BAKX Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BAKX Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.